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ABSTRACT 
 
Epilepsy is a spectrum of neurological disorders with many causal factors. The GABA type-A 
receptor (GABAAR) is a major genetic target for heritable human epilepsies. Here we examine the 
functional effects of three epilepsy-causing mutations to the 1 subunit (1T10’I, 1D192N and 
1A295D) on inhibitory postsynaptic currents (IPSCs) mediated by the major synaptic GABAAR 
isoform, 122L. We employed a neuron - HEK293 cell heterosynapse preparation to record 
IPSCs mediated by mutant-containing GABAARs in isolation from other GABAAR isoforms. IPSCs 
were recorded in the presence of the anticonvulsant drugs, carbamazepine and midazolam, and at 
elevated temperatures (22, 37 and 40 
o
C) to gain insight into mechanisms of febrile seizures. The 
mutant subunits were also transfected into cultured cortical neurons to investigate changes in 
synapse formation and neuronal morphology using fluorescence microscopy. We found that IPSCs 
mediated by 1T10’I22L, 1D192N22L GABAARs decayed faster than those mediated by 
122L receptors. IPSCs mediated by 1D192N22L and 1A295D22L receptors also exhibited a 
heightened temperature sensitivity. In addition, the 1T10’I22L GABAARs were refractory to 
modulation by carbamazepine or midazolam. In agreement with previous studies, we found that 
1A295D22L GABAARs were retained intracellularly in HEK293 cells and neurons. However, pre-
incubation with 100 nM suberanilohydroxamic acid (SAHA) induced 1A295D22L GABAARs to 
mediate IPSCs that were indistinguishable in magnitude and waveform from those mediated by 
122L receptors. Finally, mutation-specific changes to synaptic bouton size, synapse number and 
neurite branching were also observed. These results provide new insights into the mechanisms of 
epileptogenesis of 1 epilepsy mutations and suggest possible leads for improving treatments for 
patients harbouring these mutations. 
 
Key words, epilepsy, GABA receptors, synaptic inhibition, anticonvulsant, febrile 
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INTRODUCTION 
 
Epilepsy is a serious neurological condition, affecting 2-3% of the world’s population (1). It is not a 
single neurological disorder, but a diverse set of disorders arising from multiple causes, many of 
which have a genetic component (2,3). The disorders have in common the recurrence of episodic 
seizures (4). Brain regions that have been identified as sites of epileptic activity include the 
neocortex, thalamus, hypothalamus and amygdala (5). The -aminobutyric acid (type A) receptor 
(GABAAR) is emerging as a major causal agent in some forms of genetic epilepsy. Heritable 
mutations to the GABAAR , ,  and  subunits have been identified in family pedigrees of 
epilepsy (6) and new mutations continue to be identified (7,8). Studies of thalamo-cortical 
connections of the brain have demonstrated that epileptic states are preceded by the synchronisation 
of excitatory activity in neuronal populations. This hypersynchronous firing can be a result of 
impaired GABAergic inhibitory input (9), and is consistent with the presence of epilepsy-like 
symptoms in animals in which thalamic GABAARs have been selectively knocked-out by genetic 
manipulation (10). The prevailing hypothesis is that GABAergic inhibitory input is critical in 
restraining the inherent tendency of recurrently connected excitatory neurons to transition, via 
positive feedback, into synchronous epileptiform firing (5). 
The GABAAR belongs to the pentameric ligand-gated ion channel (pLGIC) family (11). Each 
subunit comprises a large extracellular N-terminal domain that incorporates the neurotransmitter 
binding site and four -helical transmembrane domains termed M1-M4 (Fig. 1). Synaptic 
GABAARs mainly consist of  (1-6),  (1-3) and  (1-3) subunits arranged in a pentameric ring 
as, ---- (12). The most abundant synaptic subtype comprises 1, 2 and 2 subunits (13). The 
GABAAR is a major therapeutic target for the treatment of epilepsy and drugs that block GABAAR 
currents, such as bicuculline and picrotoxin, can give rise to seizures (5). GABA binds at the two 
interfaces between  (+) and  () subunits in the extracellular domain of the receptor and 
benzodiazepines bind at the homologous, single - subunit interface (11). Benzodiazepines, such 
as midazolam, have been used extensively in the treatment of epilepsy (14,15). Carbamazepine is 
another commonly prescribed anti-epileptic drug that inhibits voltage-gated sodium channels (16) 
and affects other ion channels that modulate neuronal firing, such as N-methyl-D-aspartate 
receptors (17). It also enhances whole-cell currents mediated by 122 GABAARs expressed in 
HEK293 cells or neurons (18). 
In this study we sought to resolve the molecular mechanisms of epileptogenesis caused by three 
epilepsy-causing 1 mutations: 1T10’I (or 1T265I), 1D192N and 1A295D (Fig. 1), with the aim of 
identifying novel therapeutic strategies for these disorders. The 1A295D mutation, located in M3, 
gives rise to autosomal dominant juvenile myoclonic epilepsy. Its clinical presentation is not 
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associated with febrile seizures. The alanine residue at position 295 is highly conserved amongst  
subunits. Previous studies of this mutation in recombinantly expressed 1A295D–containing 
GABAARs in HEK293 cells demonstrated reduced current amplitude (19,20) and reduced cell 
surface expression (21). It is reported to result in subunit misfolding, internalisation and subsequent 
degradation via the endoplasmic reticulum degradation pathway (21). The FDA-approved drug, 
suberanilohydroxamic acid (SAHA), was shown to modestly enhance the functional expression of 
1A295D–containing GABAARs at the cell surface (22). However, the extent to which synaptic 
signalling is recovered by SAHA treatment remains to be determined. The 1D192N mutation, which 
gives rise to idiopathic generalised epilepsy with febrile seizures (23), is located in the extracellular 
domain in a region that lines the base of the GABA binding pocket. This region has been shown to 
be critical for triggering activation in GABAARs (24) and other pLGICs (25). Whole-cell current 
recordings revealed accelerated whole-cell deactivation and desensitisation (23), although it is 
unclear whether these changes alter the activation or deactivation time courses of GABAergic 
inhibitory postsynaptic currents (IPSCs). Little is known about the functional consequences of the 
1T10’I mutation. This mutation is located in the middle of the pore-lining M2 domain, near the 
permeation ‘gate’ of the receptor (25) and other residues that are critical for channel conductance 
and gating (26-30). It was recently discovered as a de novo mutation in a child with epileptic 
encephalopathy (31). 
The effects of epilepsy mutations on the magnitudes, rise and decay times of IPSCs were 
investigated in 122L GABAARs. Because it is not possible to control GABAAR subunit 
composition in neurons, we employed a heterosynapse preparation in which the postsynaptic 
GABAARs comprised only the subunits of interest (32). These recordings were also used to 
determine the effects of temperature (22, 37 and 40 
o
C) and anti-epileptic drugs (midazolam and 
carbamazepine) and on IPSC rise and decay kinetics. We also investigated the effects of SAHA on 
GABAARs incorporating the 1
A295D
 mutation (22). Finally, fluorescence microscopy was 
employed to monitor the effects of mutations and SAHA on neuronal morphology and on GABAAR 
surface expression efficiency and synapse number. 
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Figure 1. Structural model of a pentameric GABAAR showing the positions of the three epilepsy 
mutant residues (red) in a single highlighted (yellow) subunit. The left panel shows a view of the 
complex from within the plane of the membrane. The right panel shows a view from the 
extracellular space along the central pore axis perpendicular to the membrane. The model was 
generated from the 3 Å crystal structure of the homomeric 3 GABAAR (33)(PDB access code: 
4COF) and rendered in Visual Molecular Dynamics software. 
 
MATERIALS and METHODS 
HEK293 cell culture and transfection: Methods for preparing neurons and HEK293 cells for 
heterosynapse recordings have previously been detailed (32). Briefly, euthanasia of timed-pregnant 
rats was performed via CO2 inhalation as approved by the University of Queensland Animal Ethics 
Committee (approval number: QBI/142/16/NHMRC/ARC). The cortices of e18 rat embryos were 
dissected out, triturated and plated on poly-D-lysine coated coverslips at a density of ~100 x 10
3
 
cells per coverslip. The cells were bathed in DMEM medium with 10 % fetal bovine serum, then 
replaced after 24 h with Neurobasal medium, including 2 % B27 and 1 % glutamax. After one 
week, half of this medium was replaced with fresh medium. Neurons were allowed to grow for 3-4 
weeks before introducing the transfected HEK293 cells. HEK293 cells were transfected with 
cDNAs encoding human α1, β2, and γ2L GABAAR subunits (all in the pcDNA3.1 plasmid) and co-
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transfected with pEGFP and neuroligin 2A (in pNICE) at a ratio of 1:1:4:1:1, using Ca
2+
-phosphate 
co-precipitation. Synaptic currents in HEK293 cells were recorded by whole-cell patch clamp 1-3 
days later. Mutations to the 1 subunit were introduced by site-directed mutagenesis and confirmed 
by DNA sequencing of the entire plasmid. The T265I mutation in the 1 subunit will be referred to 
using the standard primed number nomenclature for transmembrane residues, in which the 0’ 
position corresponds to 1R255 in the M2 domain. 
Preparation of neurons for imaging: Primary cortical neurons were plated onto poly-D-lysine-
coated glass-bottomed dishes at a density of 10 – 15 x 104 cells per 29 mm dish and transfected with 
the α1 subunit harbouring a superecliptic pHluorin (SEpH) (Addgene plasmid 49168)(34), near its 
N terminus. The transfection was performed 7 – 10 days after plating, using Lipofectamine 200 and 
the neurons were typically imaged between DIV 25 and DIV 28. 
Electrophysiology: All heterosynapse experiments were performed in the whole-cell configuration 
of the patch-clamp technique, at a holding potential of −70 mV. The intracellular solution was 
composed of (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, and 10 EGTA, adjusted to pH 7.4 
with CsOH. Cells were perfused with extracellular solution, which contained (in mM): 140 NaCl, 5 
KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, adjusted to pH 7.4 with NaOH. Currents 
were filtered (3dB, 4-pole Bessel) at 4 kHz and sampled at 10 kHz and recorded using a 
Multiclamp 700B amplifier and pClamp 10 software. Recordings with series resistances >20 MΩ 
were discarded and series resistance compensation was not applied to the recorded cell. In 
experiments where drugs were applied, the events from the wash phase were averaged with the pre-
drug period to control for any run-down or run-up of current amplitude. The temperature of the bath 
was increased from room temperature 22 ± 2
o
C to 40 ± 2
o
C using an in-line bath heater (Warner 
TC-324B). Single channel recordings were done using excised outside-out membrane patches from 
transfected HEK293 cells at a clamped potential of −70 mV. The recorded patches were 
continuously perfused with an extracellular solution containing 3 mM GABA. Currents were 
recorded using an Axopatch 200B amplifier (Molecular Devices), filtered at 5 kHz and digitized at 
20 kHz using Clampex (pClamp 10, Molecular Devices) via a Digidata 1440A digitizer. 
Microscopy experiments: All experiments were performed on an Elyra fluorescent microscope (Carl 
Zeiss Microscopy GmbH) equipped with 100x objective (α Plan-Apochromat 100x 1.46 NA oil-
immersion), a focus lock system and an EMCCD camera Andor iXon Ultra 897 (Andor 
Technologies). This system has significantly higher sensitivity than confocal microscopes and is 
better suited for detecting the presence of GABAARs that express poorly at the cell membrane. 
Presynaptic terminals were identified using Oyster 550 labelled anti-synaptotagmin antibodies 
(Synaptic Systems Cat. No. 105 311). SEpH and Oyster 550 fluorescence was recorded with a 
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LF488/561-A-000 beam splitter and FF01-523/610-25 emission filter (Semrock). Red and green 
channels were aligned with fluorescent microspheres (Molecular Probes) and the channel alignment 
module in Zen 2012 SP2 (black) software (Carl Zeiss Microscopy GmbH). To access surface 
expression of GABAARs the HEK293 cells were fixed with 4 % paraformaldehyde in phosphate 
buffered saline for 5 min and then incubated with Atto-647N conjugated anti-GFP antibody (132 
003AT1, Synaptic Systems) for 1 h. We also quantified surface expression of GABAARs using Atto 
647N labelled antibodies against GFP in neurons. The images were taken immediately after 
washing with phosphate buffered saline. For comparative intensity analysis, the microscope settings 
were held constant for all measurements. The images were processed in Fiji (National Institutes of 
Health). GABAAR surface expression was quantified by measuring the fluorescence intensity of 
Atto-647N at the membrane surface. Identification of inhibitory synapses was conducted as 
described in (35). Briefly, synaptic contacts in neuronal cultures were defined as points of co-
localisation between the green puncta found in neurons transfected with tagged wild-type (WT) or 
mutant 1 subunits and magenta synaptotagmin rich presynaptic contacts of surrounding neurons. 
Only clusters that contained an overlapping region three or more pixels wide were considered to be 
synaptic contacts. A minimum of 12 neurons per mutation from 3 separate transfections were used 
for analysis. To determine the number synaptic contacts and the size of the presynaptic terminals, 
images were segmented by applying a threshold to create a binary mask that maximized the number 
of presynaptic terminals for analysis, while minimizing the coalescence of individual puncta (36). A 
particle detection algorithm was then applied only to regions previously found to co-localise with 
SEpH-labeled GABAAR clusters. A total of 240-260 presynaptic terminals were measured for WT 
and each of the three mutant 1 constructs. 
Statistical analyses: Data sets were first tested for normal distribution prior to using ANOVA tests 
to determine statistical significance, with p < 0.05 as the significant threshold. The tests were 
conducted with SigmaPlot software. Power analysis of our data revealed that all data sets had power 
levels between 0.8 and 1. All data are presented as mean ± SEM. 
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RESULTS 
 
Epilepsy-causing 1 mutant subunits accelerate the IPSC decay rate.  
We recorded spontaneous IPSCs mediated by 1T10’I22L, 1D192N22L and 1A295D22L 
GABAARs and compared them with those mediated by wild-type (WT) 122L GABAARs at 
room temperature (22 
o
C). All constructs with the exception of the 1A295D22L GABAARs 
mediated robust spontaneous IPSCs with magnitudes up to  900 pA (Fig. 2A, Table 1). To 
quantify the effects of mutations on cell surface expression levels, we transfected HEK 293 cells 
with the mutant subunits containing pH sensitive GFP (SEpH) near extracellular N-terminus and 
used Atto647N-conjugated antibodies to label GABAARs expressed at the cell surface (Fig. 2B). 
Quantification of the relative surface expression levels revealed the expression level of 1D192N-
containing receptors to be similar to that of 1WT-containing receptors, whereas the 1T10’I mutation 
reduced surface expression (Fig. 2C). In agreement with previous reports (20-22), spontaneous 
IPSCs were never observed in the heterosynapse preparations transfected with 1A295D-containing 
receptors (Fig. 2B). Consistent with this, antibody labelling of cells transfected with 1A295D22L 
GABAARs showed no surface labelling (not shown). We repeated these experiments after exposing 
transfected cells to suberanilohydroxamic acid (SAHA) at concentrations of either 2.5 M or 100 
nM for a period of 3 – 4 days post-transfection. After incubating with a clinically relevant (2.5 M) 
concentration of SAHA (22), IPSCs of robust magnitude were apparent in heterosynapse recordings 
(Fig. 2A). Given the effectiveness of 2.5 M SAHA, we also tested the effectiveness of a lower 
(100 nM) SAHA concentration. This also enhanced the surface expression of 1A295D22L 
GABAARs to a detectable level (Fig. 2B, C) and resulted in spontaneous IPSCs of robust magnitude 
(Fig. 2A, see also below). 
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Figure 2. Epilepsy-causing 1 mutations reduce surface expression but form functional synapses in 
heterosynaptic cultures. A. Sample recordings of spontaneous IPSCs mediated by GABAARs with 
the indicated subunit compositions. The 1A295D22 GABAAR did not mediate IPSCs unless it was 
pre-incubated with SAHA. Green traces represent sample recordings with no SAHA treatment (top 
green trace), 2.5 M SAHA for 3 days (middle green trace) or 100 nM SAHA for 3 days (bottom 
green trace). B. Sample images of HEK293 cells expressing the following GABAARs (from top to 
bottom): 122, 1T10’I22, 1D192N22 and 1A295D22. Cells expressing 1A295D22 
GABAARs were treated with 2.5 M SAHA for 3 days. C. Quantification of surface expression for 
the experiment in C. The 1T10’I22 and 1A295D22 receptors exhibited significantly reduced 
expression levels (***p<0.001). 
 
As the 1T10’I mutation occurs within the pore-forming M2 transmembrane domain, we also 
explored the possibility that the mutation may affect the ability of the pore to flux current. Thus, 
single channel recordings were carried out by exposing membrane patches excised from HEK293 
cells expressing either 122L or 1T10’I22L GABAARs to 3 mM GABA (Fig. 3A). Single 
channel amplitudes for each receptor were determined by plotting frequency histograms of current 
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magnitudes and fitting these to Gaussians (Fig. 3B). The fitted histograms revealed that WT single 
channel amplitude was 1.94 pA, whereas that for the mutant was 1.83 pA. These measurements 
demonstrate that the 1T10’I mutation does not change the unitary conductance to an appreciable 
degree and suggests that mutation affects other aspects of receptor function. 
 
Figure 3. Comparison of the single channel conductances for 122L and 1T10’I22L 
GABAARs A. Sample single channel recordings for the 122L GABAARs (above) and the 
1T10’I22L GABAARs (below) in response to a saturating (3 mM) GABA concentration. B. 
Amplitude histograms for the 122L GABAARs (left) and the 1
T10’I22L GABAARs (right) 
fitted to single Gaussians. The corresponding peaks are at 1.94 pA for WT and 1.83 pA for the 
mutant. 
 
We next proceeded to quantify the decay time constants, 10 - 90 % rise times and peak current 
amplitudes of spontaneous IPSCs activated by the WT and mutant GABAARs. Cell transfected with 
the 1A295D were exposed to 2.5 M SAHA for 2 – 4 days prior to recording IPSCs. Examples of 
digitally averaged, normalised and overlayed IPSCs for the WT and all three 1 mutant-containing 
GABAARs are shown in Fig. 4A, and the averaged decay time constants, 10 – 90 % rise times and 
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peak current amplitudes are presented in Fig. 4B - D and summarized in Table 1. The IPSC decay 
rates for 122L and 1A295D22L GABAARs were similar to each other (19 - 26 ms), whereas 
those for the 1T10’I- and 1D192N-containing GABAARs were significantly faster, at 12 - 14 ms 
(Fig. 4A, B; Table 1). A previous study on 1A295D-containing GABAARs expressed in HEK293 
cells reported that this mutation accelerated the current decay rate in macropatch experiments 
without altering the single channel conductance (20). Our measurement of the IPSC decay rates of 
this mutant, although tending towards faster times, were not significantly different compared to WT 
controls (Fig. 4B). 
The IPSC rise times for all four receptors ranged between 2.5 and 1.5 ms (Fig. 4C). Only the 
1D192N- and 1A295D-containing GABAARs mediated IPSCs that rose to peak at significantly 
slower rates (Table 1). Peak IPSC amplitudes for all four receptors were variable, reflecting cell-to-
cell variation in receptor expression and synapse number, but averaged to similar levels (Fig. 4D). 
 
Figure 4. Effects of epilepsy mutations on the properties of spontaneous heterosynaptic IPSCs at 22 
o
C. A. Averaged, superimposed, normalised IPSCs mediated by 122L (black), 1T10’I22L 
(red), 1D192N22L (blue) and 1A295D22L (green) GABAARs revealing faster decay times for 
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the 1T10’I22L and 1D192N22L receptors. B. Mean IPSC decay time constants for the four 
constructs. C. Mean 10 – 90 % IPSC rise times for the four constructs. D. Mean IPSC amplitudes 
for the four constructs. Data for the a1A295D-containing receptors were recorded after SAHA 
treatment. * p < 0.05. 
 
The functional phenotypes underlying GABAergic impairment that emerge from the data are, first, 
the spontaneous IPSCs mediated by 1T10’I and 1D192N-containing GABAARs decay significantly 
faster than WT receptors, the 1T10’I -containing GABAARs also express at lower levels than WT, 
and finally, the 1A295D mutation precludes the surface expression of functional GABAARs. 
Surprisingly, the magnitudes of IPSCs mediated by 1A295D-containing GABAARs were completely 
rescued by a 3 – 4 day pre-incubation with 100 nM SAHA. Throughout the remainder of this study 
all data for 1A295D-containing GABAARs were recorded following the same 100 nM SAHA pre-
incubation. 
 
The effects of elevated temperature on IPSCs mediated by epilepsy-causing mutant receptors.  
As noted above, the 1D192N mutation gives rise to febrile seizures. Heterosynapse 
recordings were carried out at 22, 37 and 40 
o
C to determine whether febrile seizures may be caused 
by differential temperature-dependence of the kinetic parameters of IPSCs by WT and mutant 
GABAARs. IPSCs mediated by all receptors were more frequent at 40 
o
C (Fig. 5A). Examples of 
digitally averaged, superimposed and normalised IPSCs (Fig. 5B) suggest that IPSCs mediated by 
122L and 1T10’I22L GABAARs decayed more slowly than those mediated by 1
D192N22L 
and 1A295D22L GABAARs at 40 
o
C. Fig. 5C shows the mean IPSC decay time constants 
recorded at 22 and 40 
o
C for each receptor. As expected, the decay time constants in each case were 
dramatically reduced at 40 
o
C. However, the decay time constants for the 1D192N22L and 
1A295D22L GABAARs were reduced further than those mediated by 122L or 1
T10’I22L 
GABAARs (Fig. 5C, Table 1). Fig. 5D and E compares rise times and peak amplitudes, 
respectively, at 22 and 40 
o
C. It is evident that 1T10’I22L GABAARs activated at a faster rate 
than the others at 40 
o
C (Fig. 5D). Although we observed a trend to higher amplitude IPSCs in 
response to the elevated temperature, only the 1T10’I22L GABAARs showed a significant 
increase (Fig. 5E). 
We also sought to quantify changes in IPSC properties under simulated febrile seizure 
conditions, i.e., as temperature increased from 37 to 40 
o
C. Although there was no significant 
change in IPSC decay time constant for any of the receptors (Fig. 5F), IPSCs mediated by 
1D192N22L GABAARs activated more rapidly at 40 
o
C (Fig. 5G). Measurements of IPSC peak 
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amplitudes revealed no significant changes at 40 
o
C compared to 37 
o
C for any of the receptors 
(Fig. 4G). 
 
 
 
Figure 5. Effects of elevated temperature on IPSC properties. A. Sample recordings of IPSCs 
mediated by the indicated GABAARs at 40 
o
C. B. Digitally averaged, superimposed, normalised 
IPSCs mediated by 122L (black), 1T10’I22L (red), 1D192N22L (blue) and 1A295D22L 
(green) GABAARs. C. Comparison of mean IPSC decay time constants for the four constructs at 22 
and 40 
o
C. D. Comparison of mean 10 – 90 % IPSC rise times for the four constructs at 22 and 40 
o
C. E. Comparison of mean IPSC magnitudes for the four constructs at 22 and 40 
o
C. F-H. Effect of 
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increasing temperature from 37 – 40 oC on IPSC decay time constant, rise time and amplitude. Data 
represent measurements at 37
o
C and 40 
o
C from the same cells for 14-17 cells. * p < 0.05. 
 
 
Table 1. Summary of rise and decay time constants and peak amplitude for the indicated 
GABAARs at 22
o
C and 40
o
C. 
 
Sig
nifi
can
ce 
was 
test
ed 
usi
ng 
AN
OV
A. 
ANOVA tests within temperature groups that were different to wild-type are indicated with an 
asterisk (*), indicating p < 0.05. ANOVA tests between temperature groups for the same receptor 
are indicated with a pound (
#
), indicating p < 0.01. 
$
 Measurements after SAHA incubation for 3-4 
days. 
 
Effects of anti-epileptic drugs on IPSCs mediated by epilepsy mutant receptors. Midazolam 
and carbamazepine are widely used to treat epilepsy, and both are known to act at GABAARs 
(15,18). In an attempt to establish whether drug efficacy varied according to the mutation, we tested 
these drugs on IPSCs mediated by WT and the two 1 mutated receptors in heterosynapse 
preparations. Each drug-test recording was paired to a drug-free control recording in the same cell. 
The results of these experiments are summarised in Figure 6A-D and Table 2. Neither drug affected 
the rise times nor peak amplitude of IPSCs mediated any of the receptors (Table 2), suggesting that 
receptor open probability was unaffected. In contrast, both drugs significantly slowed the decay rate 
of IPSCs mediated by 122L and 1D192N22L GABAARs (Fig. 6D, Table 2). This effect was 
not observed at 1T10’I22L GABAARs, which exhibited decay time constants of 15-18 ms in both 
Receptor Decay time (ms) Rise time (ms) Amplitude (pA) n 
22
 o
C 
α1β2γ2L 26 ± 2 1.5 ± 0.1 112 ± 14 30 
α1T10’Iβ2γ2L 14 ± 0.8
#
* 1.8 ± 0.1 114 ± 18 13 
α1D192Nβ2γ2L 12 ± 1
#
* 2.2 ± 0.1
#
* 149 ± 30 12 
α1A295Dβ2γ2L$ 19 ± 1 2.5 ± 0.1
#
* 155 ± 23 12 
40 
o
C 
α1β2γ2L 7.3 ± 0.6 1.2 ± 0.1 371 ± 53 17 
α1T10’Iβ2γ2L 5.9 ± 0.7 1.4 ± 0.1 313 ± 121
#
* 15 
α1D192Nβ2γ2L 5.3 ± 0.6
#
* 1.4 ± 0.1
#
* 121 ± 20
#
* 17 
α1A295Dβ2γ2L$ 5.0 ± 0.3 1.3 ± 0.1 168 ± 45
#
* 14 
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the absence and presence of midazolam and carbamazepine (Fig. 6D, Table 2). This latter result 
suggests that the 1T10’I mutation ablated the potentiating effect of the drugs. 
 
Figure 6. Effects of the anti-epileptic drugs, midazolam and carbamazepine, on IPSC decay time 
constants. A. Examples of IPSC recordings mediated by 122L GABAARs before the application 
of drugs (above), and during the application of 100 nM midazolam (middle) and 100 nM 
carbamazepine (below). B. Sample IPSCs mediated by 1T10’I22L GABAARs before the 
application of drug (above), and during the application of midazolam (middle) and carbamazepine 
(below). C. Sample IPSCs currents mediated by 1D192N22L GABAARs before the application of 
drug (above), and during the application of midazolam (middle) and carbamazepine (below). D. 
Summary of the effects of the drugs on IPSC decay time constants. * p < 0.05. 
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Table 2. Summary of rise and decay time constants and peak amplitude for the indicated 
GABAARs in the presence of midazolam and carbamazepine. 
Receptor Decay time (ms) Rise time (ms) Amplitude (pA) n 
Control 
α1β2γ2L 28 ± 3 1.4 ± 0.1 146 ± 21 15 
α1T10’Iβ2γ2L 15 ± 1 1.7 ± 0.2 116 ± 19 11 
α1D192Nβ2γ2L 14 ± 2 1.8 ± 0.2 167 ± 46 6 
Midazolam (100 nM) 
α1β2γ2L 47 ± 8* 1.4 ± 0.2 149 ± 28 9 
α1T10’Iβ2γ2L 18 ± 2 1.5 ± 0.2 95 ± 16 8 
α1D192Nβ2γ2L 23 ± 3* 1.8 ± 0.2 167 ± 49 6 
Carbamazepine (100 nM) 
α1β2γ2L 46 ± 7* 1.2 ± 0.1 125 ± 35 7 
α1T10’Iβ2γ2L 18 ± 1 1.7 ± 0.2 107 ± 16 10 
α1D192Nβ2γ2L 21 ± 3* 1.4 ± 0.1 129 ± 37 6 
 
Significance was tested using ANOVA with p < 0.05 as the threshold 
 
Epilepsy-causing 1 mutations reduce surface expression and induce morphological changes 
in neurons 
In addition to affecting the kinetic properties of GABAergic IPSCs, the epilepsy mutations may 
exert other effects on GABAergic neurons. For example, a recent study showed that two of the 
mutations investigated here, 1D192N and 1A295D, affect GABAergic bouton and dendritic spine 
formation in a mutation-specific manner, potentially leading to changes in excitatory/inhibitory 
balance (37). In addition, an epilepsy-causing mutation in the gene coding for the 2 subunit 
(GBRG2) gives rise to an increase in GABAergic neurons in specific cortical layers (38). Here we 
transfected WT and mutant 1 subunits into cultured cortical neurons to investigate how the 
mutations affected the surface expression of GABAARs, as well as neuronal morphology and 
synaptic contact formation. 
Neurons transfected with SEpH-labeled 1WT subunits showed strong surface expression in 
neurites as previously observed (37,38) (Fig. 7A, green). Also visible were synaptotagmin rich 
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presynaptic boutons of surrounding neurons (Fig. 7A, magenta). Clusters of GABAARs could be 
observed on neuronal processes. These were either co-localised with synaptotagmin and thus 
considered to be synaptic, or were otherwise considered to be extrasynaptic (39,40). Diffuse 
labelling was also present, likely reflecting the existence of a mobile extrasynaptic GABAAR 
population (41). Transfecting neurons with mutant subunits also produced synaptic and 
extrasynaptic clusters of GABAARs with some diffuse labelling, but clear morphological 
differences were also observed (Fig. 7B-E). Neurons expressing the 1D192N subunit showed lower 
levels of surface fluorescence and reduced neurite branching relative to 1WT-transfected neurons 
(Fig. 7B, F, G). On the other hand, the total number of synapses was not significantly affected (Fig. 
7H).  
Surprisingly, α1D192N-expressing cells exhibited a significant number of presynaptic 
terminals that appeared to be enlarged (Fig. 7B, right panel). We measured the size of presynaptic 
terminals formed between GABAAR clusters containing the α1
D192N
 subunit and compared it to 
neurons that had been transfected with 1WT subunits. The mean size of presynaptic terminals in 
α1WT-expressing neurons was adequately fitted by a single Gaussian with a mean diameter of 0.68 ± 
0.08 m (Fig 7I). In contrast, neurons expressing the α1D192N subunit required two Gaussians to 
adequately describe presynaptic terminal sizes associated with surface expressed GABAARs. 
Approximately 60% of the presynaptic terminals were of comparable diameter to those of the α1WT 
controls, 0.65 ± 0.05 m, whereas the remaining 40% were enlarged, 1.48 ± 0.22 m (Fig 7J). The 
enlarged presynaptic terminals covered multiple postsynaptic contacts (Fig. 7B, magnified), helping 
to explain why the total synapse number remained high in α1D192N-transfected neurons despite 
reduced surface expression. No change in presynaptic terminal size was observed in neurons 
transfected with the other two 1 mutants, indicating that this morphological change was specific to 
α1D192N. A previous study showed that introduction of the α1D192N subunit had no significant effect 
on synaptic bouton density (37), although bouton size was not quantified. 
Neurons expressing 1A295D subunits exhibited intracellular fluorescence in the soma but not 
in the neurites (Fig. 7E) consistent with the retention of this mutant in the endoplasmic reticulum 
(22). Incubation with 100 nM SAHA resulted in detectable but low levels of surface expression 
(Fig. 7C, F) similar to that observed in HEK293 cells (Fig. 2D). There was, however, no 
impairment in neurite branching relative to 1WT-transfected neurons (Fig. 7G). Consistent with the 
overall reduced level of surface expression, the total number of synapses was significantly reduced 
relative to 1WT-transfected neurons (Fig. 7H). The effects of SAHA on surface expression of 
1A295D subunits are consistent with electrophysiological data from the heterosynaptic cultures 
(Figs. 2 and 4).  
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Neurons expressing the α1T10’I subunit showed reduced expression levels compared to those 
expressing the α1WT subunit (Fig. 7D, F). The reduced surface expression observed in neurons was 
similar to that in HEK293 cells (Fig. 2D). A reduced number of synapses was also observed in 
α1T10’I- expressing neurons, and neurite branching morphology was also significantly impaired (Fig. 
7G, H).  
 
Figure 7. Effects of epilepsy mutations on primary neuronal cultures. A. Sample images of neurons 
transfected with the SEpH-tagged 1WT subunit (green). Synaptotagmin labeling is shown in 
magenta. The magnified image (right) shows clusters of synaptic GABAARs associated with 
synaptotagmin (white arrows) and clusters of extrasynaptic GABAARs (yellow arrows). B. Images 
of neurons transfected with the SEpH-tagged 1D192N subunit. Neurons showed reduced neurite 
branching and enlarged presynaptic formations. The magnified image (right) shows clusters of 
GABAARs associated with synaptotagmin immunofluorescence (white arrows). C. Images of 
neurons transfected with the SEpH-tagged 1A295D mutant after exposure to 100 nM SAHA. Note 
the reduction in number of GABAAR clusters associated with synaptotagmin. D. Images of neurons 
transfected with the SEpH-tagged 1T10’I mutant subunit, which exhibits similar features to the 
SEpH-tagged 1WT subunit, but with reduced surface expression levels. E. Sample neuron 
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transfected with SEpH-tagged 1A295D mutant without SAHA treatment. Note receptor 
internalisation in the soma. F. Comparison of the relative surface expression levels of each subunit. 
G. Comparison of the number of neurite branching points per 100 m in neurons expressing each 
subunit. H. Comparison of the number of GABAAR clusters associated with synaptotagmin. I. 
Gaussian distribution of the size of presynaptic boutons obtained from neurons expressing the 1WT 
subunit. J. Gaussian distribution of the size of presynaptic boutons obtained from neurons 
expressing the 1D192N mutant subunit. Two Gaussians were required to fit the data, indicating a 
WT-like and an enlarged population of boutons. p < 0.05 
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DISCUSSION 
 
Effects of epilepsy mutations on heterosynaptic IPSCs 
The main advantage of engineered heterosynapses is that they permit the investigation of the 
synaptic properties of defined GABAAR isoforms in isolation from the multitude of other undefined 
GABAAR isoforms that are likely to exist in any neuron (42). Thus far, the function and 
pharmacology of GABAARs incorporating epilepsy mutations have been investigated using 
conventional whole-cell recordings of GABA-activated currents in heterologous expression systems 
such as oocytes or HEK293 cells (1,19,21). To date, little is known about how epilepsy mutations 
affect GABAergic IPSCs. 
   The heterosynapse preparation enabled us to determine that the 1T10’I22L and 1D192N22L 
GABAARs compromise effective neuronal inhibition by accelerating the decay rate of IPSCs. 
However, data from both neurons and HEK293 cells indicates that both mutations also impaired the 
cell surface expression of these GABAARs. Our data also confirm that the 1
A295D22L GABAAR 
is not expressed at all at the cell surface. It is well established that a reduction or ablation of 
functional GABAAR expression in the synapse will lead to epilepsy. For example, this mechanism 
of impairment has also been demonstrated for the nonsense GABAAR epilepsy mutations, 2
Q1X
, 
2R97X, 2Q351X and 2W390X, all of which completely ablate 2 expression (43,44). This is likely to 
induce epilepsy by several mechanisms, one of which would presumably be via the de-clustering of 
GABAARs from the synapse (45). Gentamicin, which rescues full length expression of nonsense 
truncated subunits by aminoglycoside-induced stop codon read-through, has recently been shown to 
partially rescue the expression of GABAARs incorporating the 2
Q1X
 subunit (46), suggesting a 
possible new direction for epilepsy therapy. 
   SAHA (also known as Vorinostat) is an orally-available histone deacetylase inhibitor that crosses 
the blood brain barrier and is FDA-approved for human clinical use. It was previously shown to 
correct the protein folding and thereby enhance the surface expression of 1A295D-containing 
GABAARs in HEK293 cells (22). Using cell surface biotinylation experiments, these authors 
demonstrated that SAHA (2.5 M for 24 hr) increased the surface expression of 1A295D subunits 
from ~10 to 49 % of the level of 1WT subunits. Using whole-cell electrophysiological recordings, 
they showed that the same SAHA treatment produced saturating GABA-gated currents that were 10 
% of those mediated by WT receptors (22). Here we demonstrate that SAHA (100 nM for 3 days) 
restored the functional expression of 1A295D22L GABAARs in HEK293 cells to the extent that 
the peak magnitudes and decay time constants of spontaneous IPSCs mediated by these receptors 
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were not significantly different to those mediated by 122L GABAARs. This dramatic effect 
suggests SAHA may be worth investigating as a treatment for epilepsies caused by this mutation. 
 
Mutation-specific changes in neuronal morphology and GABAAR expression levels 
Epilepsy can also result from morphological alterations to GABAergic neurons (47). A 
recent study reported that overexpression of 1A295D subunits on the background of GLRA1 gene 
knock-down resulted in increased perisomatic bouton density and enhanced innervation fields in 
cultured GABAergic neurons (22). Another study employing GABAergic basket interneurons and 
glutamatergic pyramidal neurons in which the GABRA1 gene had been knocked down, also found 
morphological changes upon transfection with α1A295D subunits (37). That study reported that the 
transfection of the mutant α1A295D subunit in GABAergic basket interneurons increased the number 
of GABAergic boutons onto target cells and restored the innervation field after GABRA1 knock-
down. In pyramidal neurons, transfection of the 1A295D subunit also increased the formation of 
dendritic spines, which are sites of glutamatergic synapses (37). As SAHA was not present in the 
experiments of these other studies, the results cannot be compared with ours. Consistent with our 
results from HEK293 cells, we found that SAHA enhanced the surface expression of 1A295D 
subunits in cultured cortical neurons. This in turn reduced the number of GABAergic synapses 
without affecting neurite branching. In contrast, transfection of 1T10’I subunits reduced both the 
number of synapses and the neurite branching rate, whereas transfection of 1D192N subunits 
reduced the neurite branching rate and produced a population of enlarged presynaptic terminals. 
Although it is unclear how changes in the presynaptic terminal size and neurite branching 
morphology would affect neuronal excitability, we can be confident that reductions in GABAAR 
surface expression and number of synapses would alter the excitatory/inhibitory balance in neurons 
expressing GABAergic synapses. Together with more rapid IPSC decay rates, this could certainly 
lead to an epilepsy phenotype. 
   Although we did not investigate the molecular basis by which GABAAR mutations affect 
neuronal morphology, we note that the N-terminal domains of GABAAR 1, 2 and 2 subunits 
play a direct structural role in synaptic contact formation (48). In such a model, it seems reasonable 
to infer that mutations to, or alterations in the surface expression of, 1 subunits could interfere in 
this process. We are not aware of any studies that have reported a link between GABAAR receptor 
expression and presynaptic terminal size. 
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Effects of high body temperature 
Epilepsy with thermal seizures is a common form of epilepsy and is mostly associated with 
mutations in the 2 subunit of the GABAAR (49). One proposed mechanism by which an elevated 
temperature could lead to impaired GABAergic inhibition is by triggering the escape of mutant 
receptors from the synapse (50). Our data reveal another mechanism. By raising the temperature 
from 22  40 oC we observed that the IPSC decay times mediated by 1D192N22L and 
1A295D22L GABAARs were reduced to a greater extent than 122L and the 1
T10’I22L 
GABAARs. One of these mutant receptors (1
D192N22L) is associated with febrile seizures (23), 
whereas the other (A295D2L) is not. Similarly, our IPSC data show that the magnitude of the 
decay time decrease is similar for the 1D192N22L and 1A295D22L GABAARs, implying that 
the latter receptors might also induce febrile seizures if they expressed efficiently in synapses. 
However, when we increased temperature from 37 – 40 oC, to more realistically mimic a febrile 
seizure temperature excursion, we observed no significant effect on IPSC decay time constant for 
any of the mutants (Fig. 5F). We speculate that the greater relative responsiveness of the decay rate 
of IPSCs mediated by 1D192N22L GABAARs at 40 
o
C (Fig. 5C) and the significantly increase in 
activation rate between 37
o
C and 40
o
C (Fig. 5G) renders them more susceptible to the effects of 
elevated temperature. 
 
The effectiveness of common anti-epileptic drugs 
It is currently estimated that over 30% of people with epilepsy do not respond to currently available 
medications (51,52). Midazolam and carbamazepine are commonly used to treat symptoms of 
epilepsy and both drugs potentiated 122L and 1D192N2L GABAARs by slowing the IPSC 
decay rates, but surprisingly, neither drug affected the 1T10’I2L GABAARs. This result is similar 
to that of a benzodiazepine-resistant epilepsy-causing mutation in the 2 subunit (1) and suggests 
that benzodiazepine administration for some epilepsy-causing GABAARs may be an ineffective 
treatment. 
The 1D192N mutation occurs on the complementary () side of the GABA binding pocket (Fig. 
1A), whereas the  subunit contributes the principal (+) side. Hence, our observation that currents 
mediated by the 1D192N2L GABAARs are enhanced by midazolam is not surprising given that 
the benzodiazepine binding site is formed at the interface of the 1 (+) and 2 () subunits. 
Carbamazepine potentiates 1D192N2L GABAARs to a similar extent as midazolam. Two lines of 
evidence suggest that this compound binds to a site other than the benzodiazepine site. First, the 
current-potentiating effects of carbamazepine are unaffected by the benzodiazepine competitive 
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antagonist, flumazenil, and second, GABAARs that either lack the 2 subunit or express 3 or 5 
subunits instead of 1 are not modulated by carbamazepine (18). Although our experiments do not 
provide information regarding the location of the carbamazepine pharmacophore, we can infer that 
the mutation does not affect the binding or the signal transduction mechanism of the drug. The 
situation is evidently different for 1T10’I2L GABAARs. Here both drugs failed to have any 
modulatory effect on IPSCs. This suggests that, irrespective of where on the receptor the two tested 
drugs bind, the signal transduction for both drugs is ablated by the 1T10’I mutation. As 
carbamazepine and midazolam are routinely used to treat epilepsy, our data suggest that neither 
would be effective in treating individuals harbouring the 1T10’I mutation. 
 
CONCLUSION 
In this study we investigated the effects of three separate hereditary epilepsy mutations in the 1 
subunit of the GABAAR and made new findings regarding their mechanisms of epileptogenesis and 
its possible reversal. All three mutations significantly reduced surface expression of GABAARs in 
neurons and the 1A295D and 1T10’I mutations reduces expression in HEK293 cells. In addition, the 
1D192N and 1T10’I mutations significantly accelerated the decay rate of GABAergic IPSCs. The 
1T10’I mutation also reduced the number of GABAergic synaptic contacts in neurons. The resulting 
loss of inhibitory input would enhance the tendency of recurrently connected excitatory neurons to 
transition, via positive feedback, into synchronous hyperactivity and could thus explain the 
epileptogenic mechanism for these mutations. We showed that SAHA at clinically relevant 
concentrations restores surface expression of 1A295D22L GABAARs to the point where they 
mediate IPSCs with waveforms and magnitudes comparable to those mediated by 122L 
GABAARs. This implies SAHA may be worthy of investigation as a treatment for epilepsies caused 
by this mutation. The newly discovered de novo mutation, 1T10’I, was found to render GABAARs 
insensitive to the standard anti-epileptic drugs, midazolam and carbamazepine. The three mutant 
subunits also caused morphological changes in neurons, demonstrating that multiple factors 
combine to impair G BAergic inhibition in these epilepsies. 
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Highlights 
 Epilepsy-causing mutations in GABA receptors impair synaptic inhibition 
 Not all mutant receptors are responsive to standard anticonvulsant drugs 
 Some mutant receptors showed increased temperature sensitivity at synapses 
 Suberanilohydroxamic acid restores misfolded receptors 
 GABA receptor mutations give rise to changes in neuronal morphology 
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